# A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

> **NCT01683409** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 130 (actual)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01683409
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2014-09
- **Final completion:** 2014-11
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2019-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01683409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01683409, "A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01683409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*